Abstract
This study aimed to clarify the association between the TP53 rs1625895 polymorphism and the efficiency of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) therapy in 106 patients with diffuse large B cell lymphoma (DLBCL). All patients received six to eight courses of R-CHOP therapy as a first-line treatment. The rs1625895 polymorphism was genotyped by polymerase chain reaction with restriction fragment length polymorphism assay. The G/G genotype of the TP53 rs1625895 polymorphism was shown to be associated with a high probability of R-CHOP therapy failure in DLBCL patients according to the probability of remission as well as 5-year overall and relapse-free survivals.
Keywords:
TP53 gene; immunotherapy; non-Hodgkin lymphoma; prognostic factors.
© 2014 John Wiley & Sons Ltd.
Publication types
-
Clinical Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Disease-Free Survival
-
Doxorubicin / administration & dosage
-
Female
-
Follow-Up Studies
-
Humans
-
Lymphoma, Large B-Cell, Diffuse / drug therapy
-
Lymphoma, Large B-Cell, Diffuse / genetics*
-
Lymphoma, Large B-Cell, Diffuse / mortality*
-
Lymphoma, Large B-Cell, Diffuse / pathology
-
Male
-
Polymorphism, Genetic*
-
Prednisone / administration & dosage
-
Rituximab
-
Survival Rate
-
Tumor Suppressor Protein p53 / genetics*
-
Vincristine / administration & dosage
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
R-CHOP protocol
-
TP53 protein, human
-
Tumor Suppressor Protein p53
-
Rituximab
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Prednisone